Research goal
Athletic Performance & Endurance
Covers compounds researched for their effects on physical performance, endurance capacity, injury resilience, recovery speed, and body composition in athletic research contexts.
Relevant Compounds
| Compound | Class | Primary mechanism | Commonly reported for | Link |
|---|---|---|---|---|
| BPC-157 | Gastric pentadecapeptide | Tendon/ligament repair; angiogenesis; accelerated recovery from training injuries | Injury prevention, recovery speed | View profile → |
| TB-500 | Thymosin Beta-4 analogue | Actin sequestration; systemic tissue repair; anti-inflammatory | Systemic recovery, muscle repair, WADA-listed | View profile → |
| Ipamorelin | GHRP / Ghrelin mimetic | Selective GH release; lean mass support; recovery enhancement | GH pulse, lean mass, recovery | View profile → |
| CJC-1295 | GHRH analogue | GHRH receptor agonism; sustained GH elevation; IGF-1 increase | GH axis support, body composition | View profile → |
| Tesamorelin | GHRH analogue | FDA-approved GHRH analogue; strong GH stimulation; visceral fat reduction | GH stimulation, recomposition | View profile → |
Research Context
The GH/IGF-1 axis occupies a central position in performance physiology research. Growth hormone stimulates hepatic and peripheral production of IGF-1, which in turn drives muscle protein synthesis, satellite cell activation, and connective tissue remodelling. GH secretagogues — including GHRH analogues such as CJC-1295 and Tesamorelin, and ghrelin mimetics such as Ipamorelin — are investigated as indirect amplifiers of this axis, working through the pituitary rather than bypassing it. Research has investigated these compounds for their potential role in supporting lean mass accrual, recovery signalling, and body composition changes under training loads, with the pulsatile GH release they induce considered closer to physiological patterns than exogenous administration.
Injury resilience is a performance variable rarely discussed in pharmacological research but highly relevant in applied contexts. Connective tissue — tendons, ligaments, and fascial structures — is slow to recover from mechanical overload and is the primary source of chronic training-related downtime. BPC-157 and TB-500 have both been investigated for their potential roles in accelerating connective tissue repair through distinct but complementary mechanisms: BPC-157 via upregulation of angiogenesis and growth factor signalling at injury sites, and TB-500 via its role in actin dynamics and systemic anti-inflammatory signalling. Research has investigated BPC-157 for its potential role in tendon and ligament repair; anecdotal reports suggest improvement in recovery timelines following overuse injuries.
Researchers and competitive athletes should note that TB-500 (and its parent molecule Thymosin Beta-4) are listed on the WADA Prohibited List under the category of peptide hormones and related substances. BPC-157 is similarly prohibited in competitive sport. This distinction between preclinical or research-context use and competitive athletics is important: the presence of these compounds on prohibited lists reflects their perceived performance-enhancing potential, but it also means any competitive athlete subject to drug testing should regard these compounds as incompatible with competition regardless of their research status.
Compound Notes
BPC-157
A 15-amino acid peptide derived from a gastric protein, BPC-157 has been extensively studied in rodent models for its effects on tendon and ligament repair, angiogenesis at injury sites, and recovery acceleration following surgical or mechanical damage. Research has investigated BPC-157 for its potential role in reducing recovery time from musculoskeletal injuries; anecdotal accounts in athlete communities are widespread, though controlled human trial data remains limited. BPC-157 is prohibited under WADA rules.
TB-500
TB-500 is a synthetic analogue of Thymosin Beta-4, a naturally occurring peptide involved in actin polymerisation and cell migration. Its systemic anti-inflammatory properties and role in mobilising stem cells to sites of injury have made it a subject of interest in recovery research. Anecdotal reports suggest improvement in systemic recovery from heavy training, and it is commonly reported in combination with BPC-157 for additive effect. TB-500 is prohibited under WADA rules for competitive athletes.
Ipamorelin
Ipamorelin is a selective GHRP that stimulates pituitary GH release via the ghrelin receptor without meaningfully elevating cortisol or prolactin — a property that distinguishes it from earlier GHRPs like GHRP-6. Its clean side effect profile and selectivity have made it a widely referenced compound in GH axis research. Commonly reported doses range from 100 to 300 mcg per injection, typically administered in proximity to sleep or training. Research has investigated Ipamorelin for its potential role in lean mass support and recovery enhancement.
CJC-1295
CJC-1295 is a GHRH analogue with an extended half-life achieved through DAC (Drug Affinity Complex) technology in its DAC form, or as CJC-1295 without DAC (also referred to as Mod GRF 1-29) for shorter-duration pulsatile release. It binds GHRH receptors on pituitary somatotrophs to amplify GH secretion and, downstream, IGF-1 production. Research has investigated CJC-1295 for its potential role in body composition and GH axis support; it is commonly reported in combination with Ipamorelin to engage both the GHRH and ghrelin pathways simultaneously.
Tesamorelin
Tesamorelin is an FDA-approved GHRH analogue (approved under the brand name Egrifta for HIV-associated lipodystrophy) and represents the most clinically validated compound in the GHRH class. It produces strong, physiologically patterned GH stimulation and has demonstrated significant reductions in visceral adipose tissue in clinical trials. Research has investigated Tesamorelin for its potential role in body recomposition beyond its approved indication; its approval status gives it a uniquely robust evidence base relative to other GHRH analogues.
Commonly Reported Combinations
Wolverine Stack — BPC-157 + TB-500
The combination of BPC-157 and TB-500 is one of the most widely discussed protocols in research communities focused on injury recovery. BPC-157's local tissue repair and angiogenic effects are commonly reported alongside TB-500's systemic anti-inflammatory and stem cell mobilisation activity, with users reporting additive or complementary outcomes. Both compounds are WADA-prohibited.
View Wolverine stack →CJC-IPA Stack — CJC-1295 + Ipamorelin
The CJC-IPA combination is among the most commonly reported GH secretagogue protocols. CJC-1295 stimulates the GHRH receptor to amplify GH output; Ipamorelin stimulates the ghrelin receptor to trigger GH release through a separate pathway. The combination engages both mechanisms simultaneously, and anecdotal reports suggest a synergistic GH pulse greater than either compound alone. Research has investigated this combination for its potential role in body composition, lean mass, and recovery.
View CJC-IPA stack →Frequently Asked Questions
Why are BPC-157 and TB-500 WADA-prohibited?
WADA prohibits substances with the potential to enhance performance, including peptides that accelerate tissue repair or recovery, even if those substances are not approved pharmaceuticals. BPC-157 and TB-500 (along with Thymosin Beta-4 itself) are listed because they are believed to confer a performance advantage by reducing downtime from injury and accelerating physiological recovery. Their prohibited status does not reflect a determination on safety but on their potential to provide an unfair competitive advantage.
How do GH secretagogues differ from exogenous human growth hormone (hGH)?
Exogenous hGH bypasses the hypothalamic-pituitary axis entirely, delivering supraphysiological GH directly. GH secretagogues — including GHRH analogues and GHRPs — instead stimulate the pituitary's own somatotroph cells to release GH, preserving the physiological feedback loops that regulate GH levels. The result is a pulsatile release pattern that more closely mirrors endogenous secretion, and the GH produced remains subject to normal somatostatin-mediated suppression. This is considered a meaningful mechanistic distinction in research contexts, though both classes are prohibited in competitive sport.
Is BPC-157 researched for injury prevention or only treatment after injury?
Most preclinical research on BPC-157 involves administration following an induced injury — testing its ability to accelerate repair in already-damaged tissue. Research has investigated BPC-157 for its potential role in promoting angiogenesis and growth factor expression at injury sites. Anecdotal reports from research communities describe use during high-volume training phases as a prophylactic measure, though no controlled human trials have evaluated this application specifically. The mechanistic basis for a preventive effect (enhanced baseline connective tissue vascularity) is plausible but remains speculative.
What does commonly reported protocol timing look like relative to training sessions?
Commonly reported protocols for GH secretagogues describe administration either immediately post-training or at sleep onset, as GH pulses naturally occur during slow-wave sleep. For BPC-157 and TB-500, timing relative to training is less consistently reported; some accounts describe post-training SubQ injection near injury sites for BPC-157, and systemic SubQ or IM for TB-500. These are anecdotal accounts and do not constitute clinical guidance.